Should I buy or sell Motus GI stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Motus GI in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MOTS shares. View MOTS analyst ratings or view top-rated stocks .

What is Motus GI's stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Motus GI's shares. Their MOTS share price targets range from $20.25 to $37.50. On average, they predict the company's stock price to reach $28.88 in the next twelve months. This suggests a possible upside of 37,993.7% from the stock's current price. View analysts price targets for MOTS or view top-rated stocks among Wall Street analysts .

How have MOTS shares performed in 2024?

Motus GI's stock was trading at $1.2750 at the start of the year. Since then, MOTS stock has decreased by 94.1% and is now trading at $0.0758. View the best growth stocks for 2024 here .

Are investors shorting Motus GI?

Motus GI saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 23,200 shares, a decline of 63.9% from the March 15th total of 64,200 shares. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.5% of the company's shares are sold short. View Motus GI's Short Interest .

When is Motus GI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our MOTS earnings forecast .

How were Motus GI's earnings last quarter?

Motus GI Holdings, Inc. (NASDAQ:MOTS) issued its earnings results on Monday, March, 18th. The company reported ($4.13) EPS for the quarter. The firm earned $0.06 million during the quarter.

When did Motus GI's stock split?

Motus GI's stock reverse split before market open on Thursday, November 2nd 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Motus GI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Motus GI investors own include Matinas BioPharma (MTNB) , Allena Pharmaceuticals (ALNA) , VYNE Therapeutics (VYNE) , Rigel Pharmaceuticals (RIGL) , TherapeuticsMD (TXMD) , Sorrento Therapeutics (SRNE) , Pfizer (PFE) , Gilead Sciences (GILD) and Marinus Pharmaceuticals (MRNS) .

When did Motus GI IPO?

Motus GI (MOTS) raised $21 million in an initial public offering on Wednesday, February 14th 2018. The company issued 3,500,000 shares at a price of $5.00-$7.00 per share. Piper Jaffray acted as the underwriter for the IPO and Oppenheimer & Co. was co-manager.

How do I buy shares of Motus GI?

Shares of MOTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MOTS

Motus GI (MOTS) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free MOTS Stock Alerts

$0.08

+0.01 (+8.29%)

(As of 05:38 PM ET)

Compare

Today's Range: $0.07
▼
$0.08
50-Day Range: $0.07
▼
$1.10
52-Week Range: $0.07
▼
$23.40

Volume: 196,527 shs
Average Volume: 1.44 million shs
Market Capitalization: $381,274.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.88

Get Motus GI alerts:

Motus GI MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 37,993.7% Upside
$28.88 Price Target
Short Interest: Healthy
0.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Motus GI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Motus GI has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.46% of the float of Motus GI has been sold short.
Short Interest Ratio / Days to Cover
Motus GI has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Motus GI has recently decreased by 63.86%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Motus GI does not currently pay a dividend.
Dividend Growth
Motus GI does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MOTS.

0.9

News and Social Media Coverage

News Sentiment
Motus GI has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Motus GI this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for MOTS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Motus GI insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.57% of the stock of Motus GI is held by insiders.
Percentage Held by Institutions
Only 20.06% of the stock of Motus GI is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Motus GI is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Motus GI is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Motus GI has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Motus GI Stock (NASDAQ:MOTS)

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.

MOTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MOTS Stock News Headlines

April 16, 2024 | morningstar.com

Motus GI Holdings Inc

April 12, 2024 | msn.com

Why Is Motus GI (MOTS) Stock Down 37% Today?

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 12, 2024 | investorplace.com

Why Is Motus GI (MOTS) Stock Down 37% Today?

March 23, 2024 | msn.com

Motus GI Holdings files to sell 4.4M common shares for holders

March 19, 2024 | finanznachrichten.de

Motus GI Holdings, Inc.: Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 18, 2024 | investorplace.com

MOTS Stock Earnings: Motus GI Hldgs Misses EPS, Misses Revenue for Q4 2023

March 18, 2024 | fr.investing.com

Le BPA de Motus GI Holdings a dépassé les attentes de 1,30$, le CA en dessous des prévisions

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 18, 2024 | globenewswire.com

Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 29, 2024 | finance.yahoo.com

Motus GI Holdings, Inc. (MOTS)

February 29, 2024 | businesswire.com

EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

February 23, 2024 | investing.com

Motus GI secures new patent for endoscopic procedures

February 23, 2024 | wsj.com

Motus GI Holdings Inc.

February 22, 2024 | finance.yahoo.com

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

February 22, 2024 | globenewswire.com

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

February 21, 2024 | msn.com

Why Is Colonoscopy-Focused Motus GI Stock Trading Higher Today?

February 21, 2024 | markets.businessinsider.com

Crude Oil Moves Higher; Exelon Earnings Top Estimates

February 21, 2024 | fr.investing.com

Motus GI obtient un nouveau brevet pour les procédures endoscopiques

February 21, 2024 | finance.yahoo.com

Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

February 21, 2024 | globenewswire.com

Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

February 16, 2024 | finance.yahoo.com

Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders

February 16, 2024 | globenewswire.com

Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders

February 14, 2024 | investing.com

Motus GI Holdings Inc (MOTS)

February 8, 2024 | morningstar.com

Motus GI Holdings Inc MOTS

January 30, 2024 | finance.yahoo.com

Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation

January 7, 2024 | finance.yahoo.com

There Are Reasons To Feel Uneasy About Motus Holdings' (JSE:MTH) Returns On Capital

See More Headlines

Receive MOTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Motus GI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:MOTS
CUSIP: N/A
CIK: 1686850
Web: www.motusgi.com
Phone: (954) 541-8000
Fax: 954-541-8265
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $28.88
High Stock Price Target: $37.50
Low Stock Price Target: $20.25
Potential Upside/Downside: +41,150.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($28.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,870,000.00
Net Margins: -4,033.54%
Pretax Margin: -4,033.54%
Return on Equity: N/A
Return on Assets: -110.70%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 1.76
Quick Ratio: 1.69

Sales & Book Value

Annual Sales: $320,000.00
Price / Sales: 1.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.74 per share
Price / Book: 0.04

Miscellaneous

Outstanding Shares: 5,030,000
Free Float: 4,952,000
Market Cap: $352,100.00
Optionable: Not Optionable
Beta: 1.30

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Mark Pomeranz (Age 62)
Non-Independent Director & CEO
Comp: $877.1k
Ms. Ravit Ram (Age 49)
CFO & VP of Global Operations
Comp: $371.58k
Mr. Elad Amor (Age 40)
Chief Accounting Officer
Comp: $349.87k

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Sold 448,000 shares on 2/13/2024
Ownership: 17.246%

View All Institutional Transactions

MOTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Motus GI stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Motus GI in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MOTS shares.
View MOTS analyst ratings or view top-rated stocks.
What is Motus GI's stock price target for 2024?: 1 equities research analysts have issued twelve-month target prices for Motus GI's shares. Their MOTS share price targets range from $20.25 to $37.50. On average, they predict the company's stock price to reach $28.88 in the next twelve months. This suggests a possible upside of 37,993.7% from the stock's current price.
View analysts price targets for MOTS or view top-rated stocks among Wall Street analysts.
How have MOTS shares performed in 2024?: Motus GI's stock was trading at $1.2750 at the start of the year. Since then, MOTS stock has decreased by 94.1% and is now trading at $0.0758.
View the best growth stocks for 2024 here.
Are investors shorting Motus GI?: Motus GI saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 23,200 shares, a decline of 63.9% from the March 15th total of 64,200 shares. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.5% of the company's shares are sold short.
View Motus GI's Short Interest.
When is Motus GI's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our MOTS earnings forecast.
How were Motus GI's earnings last quarter?: Motus GI Holdings, Inc. (NASDAQ:MOTS) issued its earnings results on Monday, March, 18th. The company reported ($4.13) EPS for the quarter. The firm earned $0.06 million during the quarter.

When did Motus GI's stock split?: Motus GI's stock reverse split before market open on Thursday, November 2nd 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Motus GI own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Motus GI investors own include Matinas BioPharma (MTNB), Allena Pharmaceuticals (ALNA), VYNE Therapeutics (VYNE), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Pfizer (PFE), Gilead Sciences (GILD) and Marinus Pharmaceuticals (MRNS).
When did Motus GI IPO?: Motus GI (MOTS) raised $21 million in an initial public offering on Wednesday, February 14th 2018. The company issued 3,500,000 shares at a price of $5.00-$7.00 per share. Piper Jaffray acted as the underwriter for the IPO and Oppenheimer & Co. was co-manager.
How do I buy shares of Motus GI?: Shares of MOTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MOTS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial